(Q37166085)

18 August 2017

1 reference

title

The case for combination antiviral therapy for chronic hepatitis B virus infection (English)

1 reference

18 August 2017

1 reference

1 reference

1 reference

Kathryn L Nash

1

1 reference

PubMed ID

18485825

18 August 2017

Graeme J M Alexander

series ordinal

2

1 reference

18 August 2017

14 May 2008

1 reference

Lancet Infectious Diseases

18 August 2017

1 reference

18 August 2017

8

1 reference

18 August 2017

7

1 reference

18 August 2017

444-448

1 reference

World-Wide Control of Hepatitis B

18 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

1 reference

7 January 2021

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Reversal of liver cirrhosis: a desirable clinical outcome and its pathogenic background

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Histological outcome during long-term lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Update on viral hepatitis: 2006.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

1 reference

7 January 2021

Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Comparative biology and pathogenesis of AIDS and hepatitis B viruses: related but different

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Mutation rate of the hepadnavirus genome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

The implications of drug resistance for strategies of combination antiviral chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Adefovir dipivoxil: a review of its use in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Inhibition of hepatitis B virus polymerase by entecavir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Combination therapy with lamivudine and famciclovir for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Prevention of hepatitis B virus recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970102-6

7 January 2021

10.1016/S1473-3099(08)70102-6

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18485825